Expert-quality SAPs at AI speed

BlackCat Bio's therapeutic-area AI agents cut statistical analysis plan (SAP) drafting from weeks to days, catch indication-specific issues in protocols before they become amendments, and deliver fully sourced outputs grounded in FDA guidance for your exact study type.

5
Programs supported
100%
Source-traced outputs
Power Analysis Dashboard
Drug Landscape Analysis
Relevant Trials & Statistical Decisions
Agent Recommendations
Drug Comparison
Landscape Report
Built for
CROs Biotech Sponsors Contract Statisticians Regulatory Affairs Teams Phase I–III Trials

We meet you where you are.

Protocol Review & Design
Already have a protocol? We pressure-test it against FDA guidance, CRLs, and precedent, and go further. If your endpoints, objectives, or design decisions don't hold together, we flag it and help you fix it before it reaches the agency.
SAP Review & Optimization
Beyond checking your SAP against regulatory standards, we reassess decisions like sample size and power so your trial is better designed to complete and succeed.
SAP Generation
Starting from a protocol and study design, we generate a complete, submission-ready SAP draft in days. Every decision is evidence-backed and reviewed by your statistician before anything is finalized.

From briefing to
submission-ready in days.

Unlike generic AI, BlackCat Bio deploys therapeutic-area agents trained on the specific statistical conventions, FDA precedent, and operational realities of your indication.

01
Ingest your context
Upload protocols, IND documents, FDA correspondence, slidedecks, and publications. We build a knowledge base scoped entirely to your program.
Secure document vault
02
AI agents extract statistical decisions
Our AI agents surface every statistical decision your trial requires. Each recommendation is sourced, evidence-backed, and specific to your program.
Multi-agent evidence layer
03
Statistician reviews the evidence
Your statistician — or our ex-FDA statistician serving as your study statistician — reviews the underlying rationale behind every recommendation and provides expert sign-off. Nothing proceeds without human review.
Human-in-the-loop
04
Generate, Iterate, Refine
Generate a first draft using one of your prior SAPs as a template — or start from our template library. Every draft is fully editable and open to interrogation: change a decision, regenerate a section, or request fresh agent feedback at any point in the process. The loop stays open until it’s right.
Decision-level iteration

Trusted. Validated. Secure.

Source-locked outputs
Every sentence in a generated protocol is linked to its regulatory or documentary source. Reviewers see exactly where each claim comes from. No guesswork, no exposure.
Template library
Built from publicly available SAPs from leading pharmaceutical companies and CROs, with options tailored to your indication, study phase, and design — so every draft starts from the right baseline.
Regulatory intelligence retrieval
Our platform continuously indexes FDA guidance documents, complete response letters, and agency precedents, surfacing the right regulatory context for your specific indication and phase.
Enterprise-grade security
Your data is never used for model training. Tenants are fully isolated. Secure cloud storage with access controls and audit logging
Team collaboration
Invite statisticians, medical writers, and regulatory leads into a shared workspace. Track changes, comments, and version history across every document.
Protocol & SAP generation
Full draft output for both documents: endpoints, statistical methods, estimands, sensitivity analyses, structured to FDA expectations and ICH E9(R1).

Results from the field.

Request full access →
Barbara Elashoff
Barbara Elashoff
Co-Founder & CEO
Former FDA Reviewer

Former FDA statistical reviewer with 20+ years in pharma and biotech. Barbara has reviewed hundreds of protocols and SAPs across pulmonary, autoimmune, metabolic, cardiovascular, dermatology, and analgesia. She has a proven track record of successful regulatory submissions including NDAs, PMAs, 510(k)s, and BLAs. She brings 20+ years of FDA and industry expertise to every engagement.

Shoham Das
Shoham Das
Co-Founder & CTO
AI & Systems Engineer

Software engineer and data engineering leader with a decade of experience building scalable systems across biotech, healthcare, and venture. Skilled in full-stack development, data infrastructure, and AI-powered tools that support scientists, clinicians, and investors—spanning high-throughput experimentation, therapeutic discovery, and portfolio strategy.

Kayla
Kayla Magid
Product Manager

Product Manager with 5+ years of experience building AI-focused healthtech and biotech products, backed by a Master's in Human-Computer Interaction. Passionate about crafting products that are both intuitive and impactful — eliminating friction for end users while solving real problems in the life sciences space.

Matt MacEachern
Matt MacEachern
AI Engineer

Built production systems used by investors, scientists, and internal teams — often collaborating across functions to translate real-world needs into scalable, user-focused software. Background spans both biotech and fintech, with a strong focus on end-to-end development, performance optimization, and delivering real impact through thoughtful engineering.

"
BlackCat Bio's AI tool is poised to be a game-changer for our network of consulting statisticians. By ingesting complex study protocols, FDA interactions, and more, it will allow our biostatisticians to move straight to the high-level strategic refinement that matters most. We won't just save dozens of hours. We will ensure a higher baseline of consistency and quality across every project.
Robert Rachford, CEO at BetterBiostatistics
Better Biostatistics
Ready to see what we can do
on your program?

The platform is live. SAP generation, protocol review, SAP review. Bring us your trial and we'll show you what's possible.

Pilot on your program